Farnesoid X receptor: from structure to potential clinical applications.
about
Bile acid nuclear receptor FXR and digestive system diseasesDiacylglycerol kinase θ couples farnesoid X receptor-dependent bile acid signalling to Akt activation and glucose homoeostasis in hepatocytesFarnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasisFarnesoid X receptor: from medicinal chemistry to clinical applicationsStructural requirements of the human sodium-dependent bile acid transporter (hASBT): role of 3- and 7-OH moieties on binding and translocation of bile acids.Pharmacophore-based discovery of FXR agonists. Part I: Model development and experimental validation.Identification of trisubstituted-pyrazol carboxamide analogs as novel and potent antagonists of farnesoid X receptor.Endocrine functions of bile acids.Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discoveryPharmacophore-based discovery of FXR-agonists. Part II: identification of bioactive triterpenes from Ganoderma lucidumFarnesoid X Receptor Agonist Represses Cytochrome P450 2D6 Expression by Upregulating Small Heterodimer Partner.Bile acids via FXR initiate the expression of major transporters involved in the enterohepatic circulation of bile acids in newborn mice.FXR: a target for cholestatic syndromes?Nuclear receptors as therapeutic targets in cholestatic liver diseases.Intrinsic disorder in nuclear hormone receptors.FXR an emerging therapeutic target for the treatment of atherosclerosisFarnesoid X receptor modulators: a patent review.Altered enterohepatic circulation of bile acids in Crohn's disease and their clinical significance: a new perspective.Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis.Blinded evaluation of farnesoid X receptor (FXR) ligands binding using molecular docking and free energy calculations.Clinical significance of farnesoid X receptor expression in thyroid neoplasia.Emerging drugs for the treatment of Primary Biliary Cholangitis.Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculationHematopoietically expressed homeobox is a target gene of farnesoid X receptor in chenodeoxycholic acid-induced liver hypertrophy.Preliminary structure-activity relationship on theonellasterol, a new chemotype of FXR antagonist, from the marine sponge Theonella swinhoei.Positive regulation of osteogenesis by bile acid through FXR.Antiatherosclerotic effect of farnesoid X receptor.Synthesis and Biological Evaluation of a Series of Bile Acid Derivatives as FXR Agonists for Treatment of NASH.Binding affinities of the farnesoid X receptor in the D3R Grand Challenge 2 estimated by free-energy perturbation and docking.Bile acids induce monocyte differentiation toward interleukin-12 hypo-producing dendritic cells via a TGR5-dependent pathway.Discovery of Natural Products as Novel and Potent FXR Antagonists by Virtual Screening.
P2860
Q28085493-E698C7CB-C4B4-4B8F-BE8B-E2F7D57F6466Q28114796-764A8CF7-4600-4700-BFE3-4CFE6B4FD809Q28253815-314BF364-3691-4812-88F0-B006FFB9C3FBQ28266284-E94451C4-F191-4006-BA0C-9D754AAB1587Q33650932-EF117D1E-8471-487B-BECD-FA0EEF6720E6Q34054283-6572EB55-1970-45E7-81A1-AC7E02993551Q34101208-39644EBE-E86D-4448-8C51-B959A22F088DQ34545426-1B1ED805-4CEA-4D73-A7DF-EE4E5AB522ADQ34729209-645D1396-A7FB-4D4D-908F-EBD54FE27334Q35662134-723DCF75-2D77-41B6-B3A0-AC4F559B3322Q35745253-1460F14D-BBE9-4045-8B8D-2A28E0359548Q35994016-DA831573-1174-4C63-B249-A3F4312D60B3Q36481061-A3E53867-0D93-428A-9D31-08C28211531BQ37230857-C3C302B1-4FD3-4D47-B9B8-8FF359348744Q37238407-CC71CC7E-3A1C-4300-BD97-87293064C6C3Q37334984-EFE06404-1B7B-4AE3-89B2-F689DB0D54DBQ37766898-9BD33091-A2BE-433E-A028-B58ECBAAD4F5Q38069608-5267B38C-9D1C-490C-A39D-31BB185A8B59Q38175055-64FD00D6-E9CA-4CF0-B4D0-1166538BE60AQ38597033-34460A4B-A999-4728-AC7B-8F389B72F0E1Q38648804-5C5D69D3-1279-49B6-B2F1-4C934BE8C554Q38744215-D3101524-ADE4-4A3B-9B58-19EB93C4035AQ39856124-A25800CF-B7AA-468B-92B5-C0A4F33F98D7Q39906689-ACA3F977-5F5E-4E9C-9095-E90BC5B6461BQ42365884-220A782E-DD22-47A6-8473-D9F41008171FQ43503691-2D0FF54F-32B7-422F-9A2D-5E8F3CA647EBQ46231561-3B50C095-C271-4A92-B91D-68F894A99901Q47272637-370A8C5C-A9EB-4DAD-ABA9-F1C8FD9BAD00Q48023567-E5F9C1F9-DFE6-4545-8D72-3337CCFD64AAQ53192870-5B691AE0-32B3-45E5-99C6-7D0E8A6951B7Q55360054-F345E8C1-6A03-4200-A301-199D4D979DA4
P2860
Farnesoid X receptor: from structure to potential clinical applications.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Farnesoid X receptor: from structure to potential clinical applications.
@ast
Farnesoid X receptor: from structure to potential clinical applications.
@en
type
label
Farnesoid X receptor: from structure to potential clinical applications.
@ast
Farnesoid X receptor: from structure to potential clinical applications.
@en
prefLabel
Farnesoid X receptor: from structure to potential clinical applications.
@ast
Farnesoid X receptor: from structure to potential clinical applications.
@en
P2093
P356
P1476
Farnesoid X receptor: from structure to potential clinical applications.
@en
P2093
Gabriele Costantino
Roberto Pellicciari
Stefano Fiorucci
P304
P356
10.1021/JM0582221
P407
P577
2005-08-01T00:00:00Z